Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyCRDF +2.36%28 3-1 Month Momentum % is -15.63% as of Aug. 09, 2026. GuruFocus rates CRDF with a GF Score™ of 28/100. The stock has 4 warning signs investors should review. Among 1,384 Biotechnology companies, Cardiff Oncology ranks worse than 65.03% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-09), Cardiff Oncology's 3-1 Month Momentum % is -15.63%.
The industry rank for Cardiff Oncology's 3-1 Month Momentum % or its related term are showing as below:
CRDF's 3-1 Month Momentum % is ranked worse than 65.03% of 1384
companies
in the Biotechnology industry
Industry Median: -7.155
vs CRDF: -15.63
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cardiff Oncology 3-1 Month Momentum % Related Terms
CRDF vs MNOV, PMVP, CING: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Cardiff Oncology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a 3-1 Month Momentum % of -15.63% as of Aug. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cardiff Oncology and its competitors. According to the industry distribution chart, Cardiff Oncology ranks #900 out of 1384 companies in the Biotechnology industry, placing it in the top 65%.
Is Cardiff Oncology's 3-1 Month Momentum % too high?
Cardiff Oncology's current 3-1 Month Momentum % is -15.63%. Based on the distribution chart, Cardiff Oncology ranks #900 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's 3-1 Month Momentum % compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #900 out of 1384 companies for 3-1 Month Momentum %. This places Cardiff Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current 3-1 Month Momentum % is -15.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current 3-1 Month Momentum % of -15.63%. The current 3-1 Month Momentum % is -15.63%. Cardiff Oncology's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current 3-1 Month Momentum % is -15.63% as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
28GF Score
Get the complete analysis for CRDF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
